PHAR Pharming Group N.V. ADS, each representing 10 ordinary shares Pharmaceutical Preparations Best Pharmaceutical Stocks 2026 →

PHAR Stock Analysis: Buy, Sell, or Hold?

$13.40
+0.18 (+1.36%) ▲
5d: +7.54% 30d: +41.95% 90d: +8.5%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (24%)
Quality Score
21/100
Position
EXTENDED
30-Day Fair Range
$9.59 – $12.51
Position: EXTENDED
Forward P/E & Valuation
74.4x CHEAP
vs 167.6x historical avg
Wall Street Target
$35.10
+161.9% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$11.75 / $13.48
Trend: Downtrend
💡Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: PHAR shows conflicting indicators. Wait for confirmation before entering.

Get Alerted When PHAR Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

In-depth Analysis How we analyze

Valuation Analysis: PHAR is currently trading at $13.40, which is considered extended relative to its 30-day fair value range of $9.59 to $12.51. From a valuation perspective, the stock is trading at a discount (Forward PE: 74.4) compared to its historical average (167.6). Remarkably, the market is currently pricing in an annual earnings decline of 23.7% over the next few years. This pessimistic expectation contrasts with the company's recent 74.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.

Technical Outlook: Technically, PHAR is in a downtrend. The price is approaching resistance at $13.48. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.

Market Sentiment: PHAR scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $35.10 (+161.9%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position EXTENDED
Historical Trading Range $9.59 - $12.51
Company Quality Score 21/100 (STRONG SELL)
Volume Confirmation HIGH
Confidence Score 23.8%

Trading Range & Key Levels

30-Day Trading Range $9.59 - $12.51
Current vs Trading Range EXTENDED
Support Level $11.75
Resistance Level $13.48
Current Trend Downtrend
Technical data as of Nov 11, 2026

Quantitative Signal Breakdown

  • BEARISH: Price extended above range (+7.1% above its trading range)
  • BEARISH: Weak technical setup (0/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 161.9% below Wall St target ($35.10)
  • WARNING: Composite score 21/100 in the bottom quintile — this cohort historically lags the market

Fundamental Context

Forward P/E (Next Year Est.) 74.44
Wall Street Target $35.10 (+161.9%)
Revenue Growth (YoY) 20.8%
Earnings Growth (YoY) 74.9%
Profit Margin 6.2%
Valuation Discount vs History -23.7% cheaper
PE vs Historical 74.4 vs 167.6 CHEAP
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -23.7% (market-implied from PE analysis)
1-Year Target $12.06 (-10%)
2-Year Target $10.85 (-19%)
3-Year Target $9.77 (-27%)
3-Yr Target (if PE normalizes) (PE: 74→168) $21.99 (+64%)
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 74.4, Growth: -30.8%) $9.77 (+-27%)
Base: (SPY PE: 19.9, Growth: -30.8%) $2.61 (-81%)
Bear: (PE: 16.9, Growth: -30.8%) $2.22 (-84%)
📈 Valuation based on Current Earnings
Trailing PE: 41.31 | Current EPS (TTM): $0.32
Bull Case $8.18 (-39%)
Analyst growth -43.8%, PE expands to 45.4
Base Case $7.44 (-45%)
Market implied -43.8%, PE stable at 41.3
Bear Case $8.99 (-33%)
Severe decline -20.0%, PE contracts to 35.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 74.4 to 167.6
Stabilization Target: $30.17 (+125.1%)
PE Expansion Potential: +125.1%
Share PHAR Analysis

Share this live PHAR analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.

bloggers & journalists: you are free to use our charts with attribution.

Reddit & Retail Trader Sentiment (PHAR)

Bullish 1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Oct 27, 2026
Daily AI digest
AI Retail Discussion Summary: Pharming Group reported strong Q3 2026 financial results, exceeding revenue expectations and announcing positive Phase II data for leniolisib in various indications, leading to bullish sentiment on $PHAR.
Key Retail Themes: Strong Q3 revenue growth Positive Phase II data for leniolisib
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams. View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 4:29 AM ET
Data refreshes hourly during market hours. Next update: 5:29 AM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for PHAR.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
KYMR
Kymera Therapeutics Inc
STRONG BUY
24 analysts
$145 31 SELL
ARGX
argenx NV ADR
STRONG BUY
23 analysts
$1147 35 SELL
BNTX
BioNTech SE
BUY
21 analysts
$114 62 BUY
IRD
Opus Genetics, Inc.
STRONG BUY
18 analysts
$13 41 HOLD
MRUS
Merus BV
STRONG BUY
17 analysts
$97 39 SELL

Explore More Analysis & Live Quant Tools

Part A: Deep-Dive PHAR Research Pages
PHAR Technical Chart PHAR Price Prediction PHAR Intrinsic Value DCF PHAR Earnings Date PHAR Investment Advisor PHAR Fair Price Analyzer PHAR Competitors
Part B: Tradestie Flagship Market Scanners
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals